raltegravir + rifapentine

Raltegravir + rifapentine is a combination of two pharmaceutical agents used primarily in the management of HIV infection and latent tuberculosis (TB) co-infection. Raltegravir is an HIV integrase inhibitor that blocks the integration of viral DNA into the host genome, thereby reducing viral replication and load[1][4]. Rifapentine is a rifamycin-class antibiotic that inhibits bacterial DNA-dependent RNA polymerase, suppressing RNA synthesis and leading to cell death; it has potent activity against Mycobacterium tuberculosis[6]. This combination can be used for patients with HIV who require treatment or prophylaxis for latent TB infection. Pharmacokinetic studies indicate that once-weekly rifapentine can be safely coadministered with raltegravir in this context[3][5].